Alector presents baseline characteristics for invoke-2 phase 2 clinical trial of al002 at the alzheimer's association international conference® 2024 (aaic®)

--invoke-2 is the first global phase 2 trial evaluating the safety and efficacy of a trem2 agonist, al002, in slowing disease progression in individuals with early alzheimer's disease (ad)-- --baseline characteristics data for the invoke-2 study confirm a representative study population that enables testing of the effects of a novel trem2 agonist in early ad--
ALEC Ratings Summary
ALEC Quant Ranking